ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2505

Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina

Luciano Fernando Lo Giudice1, Maria Laura Acosta Felquer 1, Luis Daniel Mazzuoccolo 2, Maria Laura Galimberti 2 and Enrique Soriano 3, 1Hospital Italiano de Buenos Aires, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 2Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 3Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Biologics, DMARDs and seronegative spondyloarthropathy, psoriasis, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 12, 2019

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: As psoriasis (Pso) commonly precedes psoriatic arthritis (PsA), an important unanswered question is whether treatment of Pso might influence the development of PsA in patients with psoriasis.

The objective of this study was to analyze the incidence of PsA in a large cohort of patients with PsO according to different treatments, with the hypothesis that treatment with biologics might prevent the development of PsA.

Methods: Patients with PsO without PsA followed at a University Hospital were included in this retrospective cohort study. Data was obtained from the Hospital Electronic Medical Record (EMR). Patients were classified according to their treatment in topics group (topic and phototherapy), conventional DMARDs (cDMARDs) group (Methotrexate (MTX) and cyclosporine (Cyc)), and biologic DMARDs group (bDMARDs) (TNFi, IL17i, and IL12-23i). Patients contributed time since beginning of the corresponding treatment until diagnosis of PsA, lost of follow up, end of treatment or end of study. Incident cases of PsA were attributed to one treatment if developed during the administration of that treatment and up to 6 months after its discontinuation if no other treatment was started. Incident cases that developed more than one year after discontinuation of treatment were disregarded (3 cases). Incidence rate was calculated for the whole population and for each one of the treatment groups and compared with chi2test, and rate ratios were calculated as well. A multivariable logistic model for the development of PsA was analyzed by treatment groups, adjusting by other variables.

Results: 797 patients, contributed a total of 10017 patient/years. Patient’s characteristics are shown in table 1.  599 (75%) patients were treated only with topics or phototherapy, 106 (13%) with cDMARDs ( 81% MTX and 19% Cyc) and 92  (11.5%) with biologics (TNFi: 64: etanercept: 44, adalimumab:23, infliximab:6 ; IL17i: 43: 14 Ixekizumab, 29 Secukinumab; IL12-23i: (Ustekinumab) 16; some patients received more than one biologic). During follow-up 72 patients developed PsA (68 under topics; 3 under cDMARDs (2 MTX and 1 Cyc) and 1 under biologics (1 Secukinumab): Global incidence rate: 7.2 per 1000 patient/years (table 1). Although numerically the incidence of PsA in PsO patients treated with biologics was lower, the difference was not statistically significant.  In Cox regression analysis, after adjusting by sex, age, and BMI, treatment with biologics was significantly associated with a reduced risk of developing PsA: Hazard ratio (95% CI): 0.1 (0.013 – 0.7); p= 0.021.

Conclusion: Treatment with biologics in patients with PsO seemed to reduce the risk of PsA and preventing its development in this retrospective single center cohort.
*This study was achieved with a grant from PANLAR (Pan-American League Against Rheumatism).


Disclosure: L. Lo Giudice, None; M. Acosta Felquer, Eli Lilly, 8, Pfizer, 8, Montpellier, 8, Jannsen, 8, Novartis, 8; L. Mazzuoccolo, None; M. Galimberti, None; E. Soriano, Abbvie, 2, 5, 8, ABBVIE, 2, 5, 8, AbbVie, 2, 5, 8, Amber, 8, Amgen, 5, 8, AMGEN, 5, 8, BMS, 8, BRISTOL, 8, Bristol MS, 8, BRISTOL MYERS SQUIBB, 8, Bristol-Myers Squibb, 8, eli lilly, 5, 8, Genzyme, 8, GENZYME, 8, GLAXO, 2, Glaxo, 2, glaxosmithkline, 2, GlaxoSmithKline, 2, GSK, 2, Janssen, 8, Lilly, 5, 8, LILLY, 5, 8, Novartis, 2, 5, 8, NOVARTIS, 2, 5, 8, PFIZER, 5, 8, Pfizer, 5, 8, Pfizer Inc, 5, 8, Roche, 2, 8, ROCHE, 2, 8, Sandoz, 5, SANDOZ, 5, Sanofi, 5, SANOFI, 5, SANOPHY, 5, UCB, 8.

To cite this abstract in AMA style:

Lo Giudice L, Acosta Felquer M, Mazzuoccolo L, Galimberti M, Soriano E. Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/can-biologics-prevent-the-development-of-psoriatic-arthritis-in-psoriasis-patients-data-from-a-large-university-hospital-cohort-in-argentina/. Accessed April 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/can-biologics-prevent-the-development-of-psoriatic-arthritis-in-psoriasis-patients-data-from-a-large-university-hospital-cohort-in-argentina/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.